BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22164285)

  • 1. Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC.
    Galan-Moya EM; de la Cruz-Morcillo MA; Llanos Valero M; Callejas-Valera JL; Melgar-Rojas P; Hernadez Losa J; Salcedo M; Fernández-Aramburo A; Ramon y Cajal S; Sánchez-Prieto R
    PLoS One; 2011; 6(12):e28406. PubMed ID: 22164285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of mitogen-activated protein kinase kinase (MKK) 3 and MKK6 by type I interferons.
    Li Y; Batra S; Sassano A; Majchrzak B; Levy DE; Gaestel M; Fish EN; Davis RJ; Platanias LC
    J Biol Chem; 2005 Mar; 280(11):10001-10. PubMed ID: 15644321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression.
    Huth HW; Albarnaz JD; Torres AA; Bonjardim CA; Ropert C
    Cell Signal; 2016 Sep; 28(9):1283-1291. PubMed ID: 27181679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
    Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the p38 MAPK pathway in cisplatin-based therapy.
    Hernández Losa J; Parada Cobo C; Guinea Viniegra J; Sánchez-Arevalo Lobo VJ; Ramón y Cajal S; Sánchez-Prieto R
    Oncogene; 2003 Jun; 22(26):3998-4006. PubMed ID: 12821934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells.
    Chen RS; Ko JC; Chiu HC; Wo TY; Huang YJ; Tseng SC; Chen HJ; Huang YC; Jian YJ; Lee WT; Lin YW
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Dec; 386(12):1047-59. PubMed ID: 23912706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
    Ko JC; Chiu HC; Wo TY; Huang YJ; Tseng SC; Huang YC; Chen HJ; Syu JJ; Chen CY; Jian YT; Jian YJ; Lin YW
    Lung Cancer; 2013 Dec; 82(3):397-406. PubMed ID: 24138903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of MKK3 and p38 MAPK in cytokine-induced death of insulin-producing cells.
    Makeeva N; Myers JW; Welsh N
    Biochem J; 2006 Jan; 393(Pt 1):129-39. PubMed ID: 16097952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential activation of p38MAPK isoforms by MKK6 and MKK3.
    Remy G; Risco AM; Iñesta-Vaquera FA; González-Terán B; Sabio G; Davis RJ; Cuenda A
    Cell Signal; 2010 Apr; 22(4):660-7. PubMed ID: 20004242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sodium ferulate on amyloid-beta-induced MKK3/MKK6-p38 MAPK-Hsp27 signal pathway and apoptosis in rat hippocampus.
    Jin Y; Fan Y; Yan EZ; Liu Z; Zong ZH; Qi ZM
    Acta Pharmacol Sin; 2006 Oct; 27(10):1309-16. PubMed ID: 17007737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytes.
    Inoue T; Hammaker D; Boyle DL; Firestein GS
    J Immunol; 2005 Apr; 174(7):4301-6. PubMed ID: 15778394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
    Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
    Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MKK3-p38 signaling promotes apoptosis and the early inflammatory response in the obstructed mouse kidney.
    Ma FY; Tesch GH; Flavell RA; Davis RJ; Nikolic-Paterson DJ
    Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1556-63. PubMed ID: 17686961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel ASK1 Inhibitor AGI-1067 Attenuates AGE-Induced Fibrotic Response by Suppressing the MKKs/p38 MAPK Pathway in Human Coronary Arterial Smooth Muscle Cells.
    Liu Z; Shi S; Zhu H; Chen Y; Zhang Y; Zheng Z; Wang X
    Int Heart J; 2018 Nov; 59(6):1416-1424. PubMed ID: 30305582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells.
    Shin I; Kim S; Song H; Kim HR; Moon A
    J Biol Chem; 2005 Apr; 280(15):14675-83. PubMed ID: 15677464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MKK3/6-p38 MAPK negatively regulates murine MMP-13 gene expression induced by IL-1beta and TNF-alpha in immortalized periodontal ligament fibroblasts.
    Rossa C; Liu M; Patil C; Kirkwood KL
    Matrix Biol; 2005 Oct; 24(7):478-88. PubMed ID: 16046111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.
    Galan-Moya EM; Hernandez-Losa J; Aceves Luquero CI; de la Cruz-Morcillo MA; Ramírez-Castillejo C; Callejas-Valera JL; Arriaga A; Aranburo AF; Ramón y Cajal S; Silvio Gutkind J; Sánchez-Prieto R
    Int J Cancer; 2008 Jan; 122(2):289-97. PubMed ID: 17893873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p150(Glued), Dynein, and microtubules are specifically required for activation of MKK3/6 and p38 MAPKs.
    Cheung PY; Zhang Y; Long J; Lin S; Zhang M; Jiang Y; Wu Z
    J Biol Chem; 2004 Oct; 279(44):45308-11. PubMed ID: 15375157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.
    Tsai MS; Weng SH; Chen HJ; Chiu YF; Huang YC; Tseng SC; Kuo YH; Lin YW
    Mol Cancer Ther; 2012 Mar; 11(3):561-71. PubMed ID: 22053010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stress-activated kinase pathway alteration is a frequent event in bladder cancer.
    Otto KB; Acharya SS; Robinson VL
    Urol Oncol; 2012; 30(4):415-20. PubMed ID: 22154358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.